# Myelo Therapeutics GMBH

Canonical: https://abierto.us/vendors/myelo-therapeutics-gmbh-g1lnchnlyxf6

- UEI: G1LNCHNLYXF6
- CAGE: DP990
- Location: Berlin, DEU
- Awards in window: 1 (5 transactions), $0 obligated, February 28, 2024 to January 16, 2025

## Awarding agencies

- National Institutes of Health: 1 awards, $0

## Industries

- 541714 Research and Development in Biotechnology (except Nanobiotechnology): $0

## Competition

- Full and Open Competition: 1 awards

## Largest awards

- 75N93020C00005 (definitive contract): $0, National Institutes of Health Niaid. Development of Myelo001 as an Orally Applied Medical Countermeasure for the Treatment of Hematopoietic Acute Radiation Syndrome. https://www.usaspending.gov/award/CONT_AWD_75N93020C00005_7529_-NONE-_-NONE-/

---
Source: USAspending.gov award data, keyed by UEI. Obligations in the window only. Cite https://abierto.us/vendors/myelo-therapeutics-gmbh-g1lnchnlyxf6.